US 7611693
Mechanism-based targeted pancreatic beta cell imaging and therapy
granted A61KA61K51/0497A61P
Quick answer
US patent 7611693 (Mechanism-based targeted pancreatic beta cell imaging and therapy) held by The Board of Regents of the University of Texas System expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K51/0497, A61P, A61P1/18, A61P3/10